Crinetics Pharmaceuticals (CRNX) Other Accumulated Expenses (2017 - 2025)

Crinetics Pharmaceuticals' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.8 million for Q2 2025.

• On a quarterly basis, Other Accumulated Expenses rose 66.42% year-over-year to $1.8 million in Q2 2025; TTM through Jun 2025 was $1.8 million, a 66.42% increase from a year earlier, with the FY2024 full-year figure at $901000.0, down 72.42% from the prior year.
• Other Accumulated Expenses rose to $1.8 million in Q2 2025 per CRNX's latest filing, from $1.7 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.3 million in Q4 2023 and bottomed at $323000.0 in Q4 2021.
• The 5-year median for Other Accumulated Expenses is $906500.0 (2021), against an average of $1.0 million.
• Across the five-year window, Other Accumulated Expenses jumped 875.22% in 2023 and sank 72.42% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $323000.0 in 2021, then climbed by 3.72% to $335000.0 in 2022, then soared by 875.22% to $3.3 million in 2023, then sank by 72.42% to $901000.0 in 2024, then jumped by 99.67% to $1.8 million in 2025.
• Per Business Quant, the three latest CRNX Other Accumulated Expenses figures stand at $1.8 million (Q2 2025), $1.7 million (Q1 2025), and $901000.0 (Q4 2024).